Enlivex Therapeutics
$1.55
22
+$0.04+2.65% Wednesday 20:00
统计数据
当日最高
1.74
当日最低
1.53
52周最高
4.59
52周最低
1.15
成交量
339,922
平均成交量
64,051
市值
27.13M
市盈率
-
股息收益率
-
股息
-
即将到来
收益
2Dec预期
预期每股收益
-0.195
实际每股收益
N/A
人们还关注
此列表基于关注ENLV的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
Mesoblast
MESO
市值799.17M
Fate Therapeutics
FATE
市值417.93M
CRISPR Therapeutics
CRSP
市值4.06B
Novartis
NVS
市值244.75B
Gilead Sciences
GILD
市值98.35B
Bluebird bio
BLUE
市值108.22M
Allogene Therapeutics
ALLO
市值549.96M
Sangamo Therapeutics
SGMO
市值176.57M
Adaptimmune Therapeutics
ADAP
市值324.8M
Biomarin Pharmaceutical
BMRN
市值17.36B
分析师评级
9.5$平均价格目标
最高估值为 $13。
来自过去6个月内的 2 个评级。这不是投资建议。
买入
100%
持有
0%
卖出
0%
关于
Biotechnology
Medical Specialties
Health Technology
Manufacturing
Pharmaceutical Preparation Manufacturing
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Show more...
首席执行官
Oren Hershkovitz
员工
71
国家
IL
ISIN
IL0011319527